Citizens Jmp assumed coverage on shares of LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) in a report released on Thursday, MarketBeat.com reports. The firm set a “market outperform” rating and a $110.00 price target on the medical instruments supplier’s stock. Citizens Jmp‘s target price indicates a potential upside of 31.75% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 23rd. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $94.00 to $86.00 and set an “equal weight” rating on the stock in a research report on Thursday. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research report on Thursday. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $105.60.
Check Out Our Latest Stock Report on LeMaitre Vascular
LeMaitre Vascular Stock Performance
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.57%. The business had revenue of $67.97 million during the quarter, compared to the consensus estimate of $67.39 million. During the same period last year, the business posted $0.75 EPS. The firm’s revenue for the quarter was up 11.3% on a year-over-year basis. Equities research analysts expect that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of LMAT. Pictet Asset Management Holding SA increased its position in LeMaitre Vascular by 5.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock worth $356,000 after buying an additional 169 shares during the period. Catalyst Capital Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the first quarter worth $32,000. EverSource Wealth Advisors LLC boosted its position in shares of LeMaitre Vascular by 28.4% in the first quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier’s stock valued at $152,000 after acquiring an additional 308 shares during the period. Summit Creek Advisors LLC boosted its position in shares of LeMaitre Vascular by 0.9% in the third quarter. Summit Creek Advisors LLC now owns 49,624 shares of the medical instruments supplier’s stock valued at $4,098,000 after acquiring an additional 450 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of LeMaitre Vascular by 21.2% in the second quarter. Van ECK Associates Corp now owns 2,574 shares of the medical instruments supplier’s stock valued at $247,000 after acquiring an additional 451 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.
Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.
Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.
Further Reading
- Five stocks we like better than LeMaitre Vascular
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
